Skip to main content

Table 4 Compliance to adjuvant chemotherapy

From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer

 

No. of patients (%)

Cycle of DCS

 1

29

(96.7)

 2

25

(83.3)

S-1 administration period (month)

 3

28

(93.3)

 6

27

(90.0)

 9

23

(76.7)

 12

18

(60.0)